Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality - Wikidata - wikimedia - TriplyDB

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality

http://www.wikidata.org/entity/Q34018061

about

The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation Approximating protein flexibility through dynamic pharmacophore models: application to fatty acid amide hydrolase (FAAH)Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems C-ring cannabinoid lactones: a novel cannabinergic chemotype.A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.Quantification of anandamide, oleoylethanolamide and palmitoylethanolamide in rodent brain tissue using high performance liquid chromatography-electrospray mass spectroscopy.Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury.Endocannabinoids and traumatic brain injury Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.Update on the role of cannabinoid receptors after ischemic stroke.Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2.Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Controlled-deactivation cannabinergic ligands.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates.Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors.Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.Binge Alcohol Exposure Transiently Changes the Endocannabinoid System: A Potential Target to Prevent Alcohol-Induced Neurodegeneration.Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

P2860

Q26765747-5B61777A-8618-4F9C-A505-FFB774E76647 Q28072822-6FFA285D-D0D3-4549-B0E6-EEB7CE0B3686 Q28740837-302231BD-51BB-409E-B688-40F50BC258E9 Q28829964-9D1F5CD8-CB37-4762-8EFC-FB1914FAFB8C Q33636166-F325F9C5-BD27-4D23-9270-93A649293EC5 Q34011553-4E88319E-AD36-42CE-9BCA-3C6739EEE7E1 Q34452685-3FBAE8B1-7C00-4D8D-A642-2E36685B4927 Q34559890-ED5CE910-C89D-4D1B-B8CD-2D867F64E807 Q34659846-EC80199C-A932-4F22-9731-F0BA6D3EFDBD Q35013538-FEA8117A-8122-4F39-8EBE-DE79596068FA Q35143425-FFA3406D-1C28-4749-81FB-9D069B3E3BAE Q35193282-551B940C-20ED-4B38-9C5B-AA2ACF6C7061 Q35532072-C8815169-60FD-4392-8350-7192926A37F3 Q35624344-CDD2B13A-775D-41F0-9B80-79E39356E1FA Q35915645-8C9EFA5E-DFBB-4E60-B054-A6CF04A3B021 Q36165438-89586916-5E30-4076-8D92-729461DDFAF9 Q36345411-86FA281D-0561-47F4-BF9F-99CEB1B67868 Q36790136-2EF87E2A-1009-4733-8024-BC7265E53814 Q36795890-562E2C32-992A-4B92-9A97-10F69F6DDF16 Q36840135-4348D29D-1409-4B0B-B38F-B205BCDE4BE2 Q36971343-060C18B7-9786-40B9-AF2F-C432A345DBC8 Q37404222-201473EB-2094-4D58-9474-0BA72DE2538D Q37527191-DB9CF0A1-E922-420B-A67E-0B98C068059F Q37793366-79452BD2-790C-465E-86A6-C79AE826B64F Q38229056-FB55DB74-DD30-4C75-8AFC-7FCF25C9B78A Q38697025-ACE38FA3-1E9D-4D9E-85F4-99FC5EFF2D56 Q41161167-2145AA09-94AA-4BDC-9B76-2DD23CAFAFAF Q42272971-6FCAD26A-F414-46E9-9C4A-4C282E9A0D42 Q46318632-D996D096-D150-4391-BADD-34E5EBC436C2 Q47944859-4F5F0FE5-8295-437B-A411-8C030038D05C Q47959346-43F0F75F-4A8F-4E2E-9691-5A6C0DE8E5BF

P2860

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality

http://www.wikidata.org/entity/Q34018061

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Enhancement of endocannabinoid ...... rotective therapeutic modality

@ast

Enhancement of endocannabinoid ...... rotective therapeutic modality

@en

Enhancement of endocannabinoid ...... rotective therapeutic modality

@nl

type

label

Enhancement of endocannabinoid ...... rotective therapeutic modality

@ast

Enhancement of endocannabinoid ...... rotective therapeutic modality

@en

Enhancement of endocannabinoid ...... rotective therapeutic modality

@nl

prefLabel

Enhancement of endocannabinoid ...... rotective therapeutic modality

@ast

Enhancement of endocannabinoid ...... rotective therapeutic modality

@en

Enhancement of endocannabinoid ...... rotective therapeutic modality

@nl

P1433

Q34018061-8005E015-24A7-420D-AE0B-F21D32789AA6

P1476

Q34018061-D99C626D-5B29-4824-A5C3-4B4CD3A8624C

P2093

Q34018061-935E37E7-0CB1-47FD-BE22-AD250B417B3D

Q34018061-A51E73B1-E04D-4CAC-AD4A-3BF06EBACEED

Q34018061-BEB1A007-F8CA-48B1-898F-1EDE46B620F4

Q34018061-DCF50445-61EA-4FA8-A6EE-EAA6C6F389F8

Q34018061-E7236692-FF76-49A8-B42B-D977ED82BC4F

P2860

Q34018061-00891D34-BD51-435E-AB07-29D3FA26604F

Q34018061-025B2395-51F3-4B0B-B8D4-BC6BD4A24494

Q34018061-035F1E3A-347B-478D-A8DB-2D025B55B8B0

Q34018061-04C46E6D-A492-4292-9EED-EFD710E1CD85

Q34018061-050232BF-202E-4DAC-A21C-1643DA430D7A

Q34018061-074A2925-7D63-43BF-A377-4D98310D30A4

Q34018061-08B1C6BF-8CD4-4A49-B2EF-9225BBA6C34E

Q34018061-0C3E099C-A9F7-4874-99A4-31E5BEE8EF17

Q34018061-0CE4E682-2E82-4B9A-B7D2-55A02543261F

Q34018061-0DF5DEE3-B171-48C3-9E54-FB42EDEA0FD7

P304

Q34018061-70907FFF-E910-43E4-AFC1-48E4BD8A6E86

P31

Q34018061-C6C83AAD-83E1-4DA9-A661-227845A6EA46

P356

Q34018061-286D8392-D712-4798-85F4-4185C6BD4866

P407

Q34018061-922A9DDF-315A-4B6F-B24D-DEB929993943

P433

Q34018061-8708ECCB-2933-46C1-995F-F1B9B57040FD

P478

Q34018061-93440C6F-BCF6-4154-A36B-2BAAA01739DC

P50

Q34018061-8332AD35-3FE6-4584-9F06-2CC8922BF840

P577

Q34018061-97B5B5D7-BA90-4CC1-9730-90555763ACB2

P5875

Q34018061-DA32154C-E01C-42E3-9267-F63FBCB1A9D1

P698

Q34018061-EB52B27A-2524-4622-916E-5E6D8725D393

P921

Q34018061-0C2A2205-2597-4F44-99D7-894DEE1E27D4

Q34018061-3DD2A72E-E8BA-49B7-B4CD-F0BB221A7EC3

P932

Q34018061-DCF0463D-744F-45CC-A584-7B5944607F63

P356

J.LFS.2009.06.003

P1433

P1476

Enhancement of endocannabinoid ...... rotective therapeutic modality

@en

P2093

Ben A Bahr

http://www.w3.org/2001/XMLSchema#string

Crista Adamson

http://www.w3.org/2001/XMLSchema#string

David Butler

http://www.w3.org/2001/XMLSchema#string

David R Janero

http://www.w3.org/2001/XMLSchema#string

Jeannie Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

The endocannabinoid system as an emerging target of pharmacotherapy

A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling

A biosynthetic pathway for anandamide

Endocannabinoids control spasticity in a multiple sclerosis model

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

P304

615-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LFS.2009.06.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

15-16

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

Alexandros Makriyannis

P577

2009-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26293274

http://www.w3.org/2001/XMLSchema#string

P698

19527737

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoids

P932

2848893

http://www.w3.org/2001/XMLSchema#string